Emanuele Zucca
YOU?
Author Swipe
View article: Predicting 2-Year Time to Progression in diffuse large B cell lymphoma Using 3D CNNs on Whole-Body PET/CT Scans
Predicting 2-Year Time to Progression in diffuse large B cell lymphoma Using 3D CNNs on Whole-Body PET/CT Scans Open
Background. The aim of this study was to develop 3D convolutional neural networks (CNN) for the prediction of 2 years’ time to progression using PET/CT baseline scans from diffuse large B-cell lymphoma (DLBCL) patients. The predictive perf…
View article: Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models
Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models Open
Background: CXCR4 is a chemokine receptor frequently implicated in the pathogenesis and treatment resistance of B-cell lymphomas and other tumor types. Thus, CXCR4 targeting is explored using various approaches, including small molecules, …
View article: Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG) Open
The characteristics at diagnosis and clinical course of primary extranodal follicular lymphoma (EFL) have not been extensively described. The International Extranodal Lymphoma Study Group (IELSG) conducted an international retrospective su…
View article: 254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY
254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY Open
View article: 90 | SEVEN‐YEAR FOLLOW‐UP OF THE IELSG42 “MARIETTA” PHASE II TRIAL: DURABLE REMISSIONS FOLLOWING MATRix/RICE INDUCTION AND THIOTEPA AUTOGRAFT IN SECONDARY CNS LYMPHOMA
90 | SEVEN‐YEAR FOLLOW‐UP OF THE IELSG42 “MARIETTA” PHASE II TRIAL: DURABLE REMISSIONS FOLLOWING MATRix/RICE INDUCTION AND THIOTEPA AUTOGRAFT IN SECONDARY CNS LYMPHOMA Open
View article: 11 | PREDICTING 2‐YEAR TIME TO PROGRESSION IN DIFFUSE LARGE B‐CELL LYMPHOMA USING ARTIFICIAL INTELLIGENCE ON WHOLE‐BODY PET SCANS
11 | PREDICTING 2‐YEAR TIME TO PROGRESSION IN DIFFUSE LARGE B‐CELL LYMPHOMA USING ARTIFICIAL INTELLIGENCE ON WHOLE‐BODY PET SCANS Open
View article: 412 | IMPROVING THE PREDICTIVE VALUE OF END‐OF‐TREATMENT PET/CT IN DIFFUSE LARGE B‐CELL LYMPHOMA
412 | IMPROVING THE PREDICTIVE VALUE OF END‐OF‐TREATMENT PET/CT IN DIFFUSE LARGE B‐CELL LYMPHOMA Open
View article: 259 | IELSG49: A PHASE II TRIAL OF ACALABRUTINIB IN COMBINATION WITH TAFASITAMAB IN PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMAS
259 | IELSG49: A PHASE II TRIAL OF ACALABRUTINIB IN COMBINATION WITH TAFASITAMAB IN PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMAS Open
View article: 52 | RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED EXTRANODAL MARGINAL ZONE LYMPHOMAS: FIRST ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY
52 | RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED EXTRANODAL MARGINAL ZONE LYMPHOMAS: FIRST ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY Open
View article: 6 | FEASIBILITY OF CTDNA AND PET GUIDED THERAPY IN UNTREATED DLBCL. PRELIMINARY RESULTS OF THE SAKK 38/19 PHASE II TRIAL
6 | FEASIBILITY OF CTDNA AND PET GUIDED THERAPY IN UNTREATED DLBCL. PRELIMINARY RESULTS OF THE SAKK 38/19 PHASE II TRIAL Open
View article: 115 | THE BTK DEGRADER BGB‐16673 AND THE BCL2 INHIBITOR SONROTOCLAX SHOWS ANTI‐TUMOR ACTIVITY AS SINGLE AGENTS AND IN COMBINATION IN MARGINAL ZONE LYMPHOMA MODELS
115 | THE BTK DEGRADER BGB‐16673 AND THE BCL2 INHIBITOR SONROTOCLAX SHOWS ANTI‐TUMOR ACTIVITY AS SINGLE AGENTS AND IN COMBINATION IN MARGINAL ZONE LYMPHOMA MODELS Open
View article: Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response
Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response Open
Accurate detection of patients at high risk of treatment failure following first line immunochemotherapy in diffuse large B-cell lymphoma (DLBCL) is of paramount importance as patients might benefit from early treatment escalation. Recentl…
View article: A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA
A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA Open
This study analyzed the genetics of classic Hodgkin lymphoma (cHL) by using circulating tumor DNA (ctDNA). Two genetic subtypes were identified, differing in genetic instability mechanisms: one subtype (64% of cases) showed a higher mutati…
View article: IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas Open
Introducing Bruton’s tyrosine kinase (BTK) inhibitors has significantly improved outcomes for patients with B-cell malignancies and autoimmune disorders. However, resistance, either primary or acquired, remains a major clinical challenge. …
View article: Understandings 18 FDG PET radiomics and its application to lymphoma
Understandings 18 FDG PET radiomics and its application to lymphoma Open
Summary The early identification of lymphoma patients who fail front‐line treatment is crucial for optimizing disease management. Positron emission tomography, a well‐established tool for staging and response evaluation in lymphoma, is typ…
View article: Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update Open
The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group conducted the SAKK 35/10 randomized phase 2 trial to compare rituximab (R) alone vs R plus lenalidomide (L) as initial treatment for follicular lymphoma (FL)…
View article: <i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study Open
View article: European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies
European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies Open
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCCs) are primarily organizational recommendations, giving politicians, managers, oncology teams, patients, and patient advocacy groups a non‐technical overview…
View article: Table S4 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Table S4 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Open
Sequences of sgRNAs used for induction of ERBB4 transcription by CRISPR activation technique.
View article: Figure S1 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Figure S1 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Open
Multi-drug resistance phenotype was ruled out by the expression of MDR1 (left) and MDR2 (right) genes by real time PCR. RQ values calculated by the DDCt method. Karpas1718 (K1718) parental lines in grey and resistant in red. Data derived f…
View article: Figure S4 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Figure S4 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Open
(A) Heatmap of functionally annotated genes showing log2-scaled fold change and -log10 adjusted P-value (FDR) by RNA-seq comparing K1718 parental and resistant cells. (B) Gene set enrichment analyses (GSEA, Broad Institute) comparing paren…
View article: Figure S11 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Figure S11 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Open
Protein levels of ERBB4 was measured by FACS (A) and immunoblotting (B) in JEKO1 cells engineered to increase the expression of ERBB. Drug sensitivity for idelalisib (C) and ibrutinib (D) was evaluated in the different clones of engineered…
View article: Figure S8 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Figure S8 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Open
Levels of p-AKT (A, top) and p-ERK (B, bottom) were determined by phospho-flow cytometry upon 1µM of idelalisib. Density plots show the median MFI values of two replicates, negative control (dotted black), parental (grey), resistant (red).…
View article: Figure S3 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Figure S3 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Open
(A) Multidimensional scaling plot showing a 2-dimensional projection of distances across parental and resistant clones for RNA (GEP, top left), methylation (top right) and miRNA (bottom left) profiles. Magenta dots for resistant and pink f…
View article: Table S3 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Table S3 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Open
Panel of proteins tested in the immunoblotting or immunofluorescence experiments.
View article: Figure S19 and references for supplementary figures from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Figure S19 and references for supplementary figures from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Open
Factors associated with resistance to idelalisib in cell lines are expressed in clinical specimens. Expression levels of genes related to idelalisib resistance were studied across different subtypes of B cell lymphoma: (A) n=48 (5), (B) n=…
View article: Table S2 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Table S2 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Open
Panel of antibodies used in flow cytometry experiments.
View article: Figure S17 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Figure S17 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Open
Sensitivity to ibrutinib was evaluated by MTT assay (72h). Karpas1718 parental (top) or resistant (bottom) were exposed to 100nM decitabine (A), 5µM tazemetostat (B), or DMSO (control, black) given concomitantly (continuous lines) or 72 ho…
View article: Supplementary Table 7 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Supplementary Table 7 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Open
Clinical information on the series of serum samples from CLL clinical patients exposed to idelalisib or to ibrutinib. Samples were longitudinally acquired at different time points. Patients were paired according to similar clinical feature…
View article: Figure S16 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Figure S16 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Open
Cell viability was evaluated by MTT assay (72h). Karpas1718 parental (A) or resistant (B) were exposed to DMSO (control, black) or decitabine (100nM, red), given concomitantly (continuous lines) or 72 hours before idelalisib (pre DMSO in d…